## CLAIMS

1. Use of a checkpoint inhibitor (CPI) compound or biologic molecule in the manufacture of a medicament for the therapeutic treatment of metastases of colorectal cancer to a liver by pressure-enabled locoregional delivery through hepatic arterial infusion (HAI) to the liver in a human subject.

2. The use of claim 1, wherein the CPI compound or biologic molecule comprises a Programmed Death 1 receptor (PD-1) antagonist.

3. The use of claim 2, wherein the PD-1 antagonist is at least one of nivolumab, pembrolizumab, and cemiplimab.

4. The use of claim 1, wherein the CPI compound or biologic molecule comprises a Programmed Cell Death 1 Ligand 1 (PD-L1) antagonist.

5. The use of claim 4, wherein the PD-L1 antagonist is at least one of atezolizumab, avelumab, and durvalumab.

6. The use of claim 1, wherein the HAI is through a catheter device.

7. The use of claim 6, wherein the catheter device responds dynamically to local pressure and/or flow changes.

8. The use of claim 1, wherein the CPI compound or biologic molecule is at a dose selected from the range of 0.01-10 mg/kg.

9. Use of a checkpoint inhibitor (CPI) compound or biologic molecule in the manufacture of a medicament for the therapeutic treatment of pancreatic cancer to a pancreas by pressure-enabled locoregional delivery through pancreatic retrograde venous infusion (PRVI) to the pancreas in a human subject.

10. The use of claim 9, wherein the CPI compound or biologic molecule comprises a Programmed Death 1 receptor (PD-1) antagonist.

11. The use of claim 10, wherein the PD-1 antagonist is at least one of nivolumab, pembrolizumab, and cemiplimab.

12. The use of claim 9, wherein the CPI compound or biologic molecule comprises a Programmed Cell Death 1 Ligand 1 (PD-L1) antagonist.

13. The use of claim 12, wherein the PD-L1 antagonist is at least one of atezolizumab, avelumab, and durvalumab.

14. The use of claim 9, wherein the PRVI is through a catheter device.

15. The use of claim 14, wherein the catheter device is a pressure-enabled drug delivery device.

16. The use of claim 9, wherein the CPI compound or biologic molecule is at a dose selected from the range of 0.01-10 mg/kg.